Nasdaq1mon
Evoke Pharma Addresses FDA Update on Domperidone Supply and Highlights GIMOTI as the Only Approved Treatment for Gastroparesis
GIMOTI® (metoclopramide) nasal spray remains the sole FDA-approved treatment for diabetic gastroparesis, providing effective symptom relief and substantial cost savings compared to oral ...
The Globe and Mail1mon
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients ...
Evoke stock rockets 90% on study of Gimoti in GLP-1 users
Evoke Pharma (NASDAQ:EVOK) shares rocketed 90% early Monday on positive data for its nasal drug Gimoti in the treatment of ...
Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Yahoo Finance1mon
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Dec. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® ...